2026 Q1 Portfolio Activity
In 2026 Q1, Aisling Capital Management LP maintained a portfolio of 14 distinct positions. The most significant new addition was Eupraxia Pharmaceuticals Inc. , now representing 0.49% of the total fund value. They heavily accumulated shares in Monte Rosa Therapeutics Inc (G, increasing the position by 5.7%. Conversely, Aisling Capital Management LP completely exited their position in CalciMedica, Inc. (CALC).
Position History
hover any row below to update
Loading…
Total Positions
14
Quarter
2026 Q1
Top Holding
BBIO (79.4%)
Top 10 Concentration
99.5%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-14 of 14
Aisling Capital Management LP Full Holdings List — 2026 Q1
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
BBIO
BridgeBio Pharm...
|
Healthcare | 79.35% | 81.29% |
#1
Prev: #1
|
7.0 |
—
|
no change | no change |
P
S
|
5,089,611 | $377,954,513 | 2019 Q2 | 13F Filing | 2026-03-31 | 2026-05-05 | |||
|
SNDX
Syndax Pharmace...
|
Healthcare | 6.46% | 5.78% |
#2
Prev: #2
|
5.1 |
—
|
no change | no change |
P
S
|
1,316,806 | $30,760,588 | 2020 Q1 | 13F Filing | 2026-03-31 | 2026-05-05 | |||
|
GLUE
Monte Rosa Ther...
|
Healthcare | 5.37% | 4.82% |
#3
Prev: #3
|
5.1 |
—
|
83,333 | 5.7% |
P
S
|
1,555,664 | $25,590,673 | 2021 Q2 | 13F Filing | 2026-03-31 | 2026-05-05 | |||
|
BCAX
Bicara Therapeu...
|
Healthcare | 2.38% | 2.00% |
#4
Prev: #4
|
2.5 |
—
|
no change | no change |
P
S
|
568,919 | $11,315,799 | 2024 Q3 | 13F Filing | 2026-03-31 | 2026-05-05 | |||
|
BBOT
BridgeBio Oncol...
|
Healthcare | 1.91% | 1.48% |
#5
1
Prev: #6
|
4.3 |
—
|
453,393 | 80.3% |
P
S
|
1,018,018 | $9,111,261 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-05 | |||
|
CMPS
Compass Pathway...
|
Healthcare | 1.66% | 1.73% |
#6
1
Prev: #5
|
2.7 |
—
|
233,918 | 19.5% |
P
S
|
1,432,336 | $7,920,818 | 2023 Q3 | 13F Filing | 2026-03-31 | 2026-05-05 | |||
|
SRRK
Scholar Rock Ho...
|
Healthcare | 0.80% | 0.71% |
#7
1
Prev: #8
|
1.3 |
—
|
no change | no change |
P
S
|
77,031 | $3,786,844 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-05 | |||
|
BMEA
Biomea Fusion I...
|
Healthcare | 0.66% | 0.53% |
#8
1
Prev: #9
|
1.3 |
—
|
no change | no change |
P
S
|
2,048,757 | $3,134,598 | 2021 Q2 | 13F Filing | 2026-03-31 | 2026-05-05 | |||
|
EPRX
Eupraxia Pharma...
|
Healthcare | 0.49% | — |
#9
Prev: #—
|
3.7 |
—
|
325,000 | — |
NEW
|
325,000 | $2,353,000 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-05 | |||
|
URGN
Urogen Pharma L...
|
Healthcare | 0.41% | 0.53% |
#10
Prev: #10
|
1.2 |
—
|
no change | no change |
P
S
|
108,000 | $1,941,840 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-05 | |||
|
ACRS
Aclaris Therape...
|
Healthcare | 0.34% | 0.27% |
#11
Prev: #11
|
1.1 |
—
|
no change | no change |
P
S
|
434,455 | $1,629,206 | 2018 Q4 | 13F Filing | 2026-03-31 | 2026-05-05 | |||
|
MRKR
Marker Therapeu...
|
Healthcare | 0.09% | 0.10% |
#12
Prev: #12
|
1.0 |
—
|
no change | no change |
P
S
|
325,370 | $422,981 | 2023 Q2 | 13F Filing | 2026-03-31 | 2026-05-05 | |||
|
OKUR
OnKure Therapeu...
|
Healthcare | 0.08% | 0.05% |
#13
Prev: #13
|
1.0 |
—
|
no change | no change |
P
S
|
88,607 | $366,833 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-05 | |||
|
CALC
CalciMedica, In...
|
Healthcare | 0.00% | 0.72% |
Sold All 😨
(Was: #7) |
0.0 |
—
|
-521,114 | -100.0% |
CLOSED
|
— | $— | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-05 |
Showing 1-14 of 14 holdings